banner

 
bar

program

slides slides
bar
 
 

Genomic Profiling and Molecular Markers to Identify Targetable, Actionable, and Therapeutically Significant Genomic Alterations
in the Setting of Lung Cancer

WebCAST

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium

Internet-based program

Estimated Time to Complete Educational Activity

6.0 hours

Course Overview

In this web-based program, physicians will learn how recent developments in genomic profiling have advanced the management of lung cancer.

Release Date

November 29, 2017

Expiration Date

November 29, 2019

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period November 29, 2017 through November 29, 2019 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 16 segments totaling 6.0 hours to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.

Registration

Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

Supported by an educational grant from Roche Singapore Pte Ltd

Accreditation Statement

This activity has been planned and implemented in accordance with accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Medical School and CMEducation Resources, LLC. University of Massachusetts Medical School  is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Massachusetts Medical School designates this enduring material for a maximum of 6.0 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Other Credits

American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Program Faculty and Disclosure

Professor Nir Peled, MD, PhD, FCCP – Program Chair
Head of The Cancer Institute
Soroka Medical Center & Ben-Gurion University
Beer-Sheva, Israel
 
Advisor for and honorarium from AstraZeneca, Boehringer Ingelheim, BMS, Lilly , MSD, Novartis, Pfizer, Roche
 

David P. Carbone, MD, PhD – Session Moderator
Barbara J. Bonner Chair in Lung Cancer Research
President, International Association for the Study
  of Lung Cancer
Professor of Medicine
Director, James Thoracic Center
James Cancer Center
The Ohio State University Medical Center
Columbus OH
 
Nothing to disclose
 

Alexander Drilon, MD – Session Moderator
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY, USA

Honoraria: Exelixis, AstraZeneca, Genentech
 

Professor James CH Yang, MD, PhD  - Session Moderator
Professor, Graduate Institute of Oncology
National Taiwan University
Director, Department of Oncology
National Taiwan University Hospital
Taipei, Taiwan
 
Honoraria for speeches or advisory board duties from Boehringer Ingelheim, Eli Lilly, Bayer, Roche/Genentech/Chugai, Astellas, MSD, Merck Serono, Pfizer, Novartis, Clovis Oncology, Celgene, Merrimack, Yuhan Pharmaceuticals, BMS, Ono Pharmaceutical, Daiichi Sankyo and AstraZeneca
 

Hossein Borghaei, DO, MD
Chief, Division of Thoracic Medical Oncology
Associate Professor, Department of Hematology/Oncology
Temple University School of Medicine
Fox Chase Cancer Center
Philadelphia, PA, USA
 
Consultant: BMS, Eli Lilly, Merck, AstraZeneca, Novartis, Serono, Boehringer Ingelheim
Grant/Research Support: Merck

 
 
Prof. Reinhard Buettner, MD
Professor and Chairman
Institute for Pathology
University Hospital Cologne
Cologne, Germany
 
Grants/Research Support: German Research Foundation
 
 
D. Ross Camidge, MD, PhD
Professor of Medicine/Oncology
University of Colorado, Anschutz Medical Campus
Joyce Zeff Chair in Lung Cancer Research
Director, Thoracic Oncology
Faculty, Developmental Therapeutics Program
University of Colorado Cancer Center
Aurora, Colorado, USA
 
Consultant: Pfizer, Boehringer Ingelheim
 
 
Haiying Cheng, MD, PhD
Medical Oncologist
Montefiore Medical Center
New York, NY, USA
 
Nothing to disclose
 
 
Professor Byoung Chul Cho, MD, PhD
Yonsei Cancer Center
Yonsei University College of Medicine
JE-UK Laboratory of Molecular Cancer Therapeutics
Seoul, Korea
 
Nothing to disclose
 
 
Professor Caroline Dive, PhD
Deputy Director and Senior Group Leader
Cancer Research
UK Manchester Institute
Manchester, England
 
Grant/Research Support: AstraZeneca, Amgen, Menarini

 

Martin Filipits, MD
Associate Professor
Institute of Cancer Research
Medical University of Vienna
Vienna, Austria
 
Nothing to disclose
 
 
Enriqueta Felip, MD
Head of the Lung Cancer Unit
Oncology Department
Vall d’Hebron University Hospital
Head of Thoracic Cancer Unit
Associate Professor of Medical Oncology (School of Medicine)
Autonomous University of Barcelona
Barcelona, Spain
 
Consultant: Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; Eli Lilly and Company; Pfizer Inc; Roche; Bristol-Myers Squibb Company; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation
 

Justin Gainor, MD
Instructor, Medicine
Harvard Medical School
Assistant in Medicine
Massachusetts General Hospital
 
Consultant: Boehringer Ingelheim, Jounce Therapeutics, and Kyowa Hakko Kirin Pharm
 
 
David R. Gandara, MD
Professor
Director, Thoracic Oncology Program
Senior Advisor to Director
UC Davis Comprehensive Cancer Center
UC Davis Health
Davis, California, USA
 
Nothing to disclose
 

Nicolas Girard, MD
Professor of Respiratory Medicine and Thoracic Oncology
Claude Bernard University
Lyon, France
Senior Attending Physician
Thoracic Oncology Service
Hospices Civils de Lyon
Lyon, France
 
Speaker/Advisory Board: MS, MSD, Roche, AstraZeneca, Boehringer, Pfizer, Lilly.
 

Professor JR Gosney, BSc, MD, FRCPath
Consultant Thoracic Pathologist
Department of Pathology
Royal Liverpool University Hospital
Liverpool, United Kingdom
 
Nothing to disclose
 

Yasushi Goto, MD
Division of Internal Medicine and Thoracic Oncology
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
Department of Pulmonary and Critical Care Medicine
Mayo Clinic Minnesota
Rochester, Minnesota, USA
 
Consultant: Eli Lilly, Pfizer, Novartis, AstraZeneca, GlaxoSmithKline
Speaker’s Bureau: Eli Lilly, Pfizer, BMS, AstraZeneca, MSD, Ono, Chugai

 

Balazs Halmos, MD, MS
Director, Thoracic Oncology
Director, Clinical Cancer Genomics
Montefiore Medical Center
New York, NY, USA
 
Consultant: Foundation One, Boehringer Ingelheim, Eli Lilly, Novartis, Roche, Pfizer, AstraZeneca
Grant/Research Support: Boehringer Ingelheim, Eli Lilly, AstraZeneca, Pfizer, Novartis, Roche, BMS
 

Pasi A. Jänne, MD, PhD
Professor of Medicine
Harvard Medical School
Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Boston, MA, USA
 
Nothing to disclose
 
 
Marc Ladanyi, MD
Molecular Geneticist
Chief, Molecular Diagnostics Service
William J. Ruane Chair in Molecular Oncology
Memorial Sloan Kettering Cancer Center
New York, New York, USA
 
Nothing to disclose
 

Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Yale Cancer Center and Smilow Cancer Hospital
Associate Director for Translational Research
Yale Cancer Center
Disease Aligned Research Team (DART) Leader
Thoracic Oncology Program, Yale Cancer Center
New Haven, Connecticut, USA
 
Consultant: AstraZeneca, Eli Lilly, Merck, Pfizer, and Genentech/Roche
Reserch/grant Support: Genentech and Merck

 

Choon-Taek Lee, MD, PhD
Division of Pulmonology and Critical Care Medicine
Department of Internal Medicine
Seoul National University College of Medicine
Department of Internal Medicine and Respiratory Center
Seoul National University Bundang Hospital
Seoul, Korea
 
Nothing to disclose
 

Tetsuya Mitsudomi, MD, PhD
Vice Director and Chief of the Department of Thoracic Surgery
Aichi Cancer Center Hospital
Nagoya, Japan
 
Nothing to disclose
 
 
Tony Mok, MD
Professor and Chair, Department of Clinical Oncology
Chinese University of Hong Kong
Prince of Wales Hospital
Hong Kong
 
Advisor/consultant: AstraZeneca Pharmaceuticals LP; AVEO Pharmaceuticals, Inc.; BeiGene; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Eli Lilly and Company; GlaxoSmithKline; Merck Serono; Pfizer Inc; Roche; Taiho Pharmaceutical Co., Ltd.
Speaker: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Merck Serono; Pfizer Inc; Roche
Research/Grant Support: AstraZeneca Pharmaceuticals LP 

 

Ignatius Ou, MD
Health Science Clinical Professor
University of California, Irvine
School of Medicine
Irvine, California, USA
 
Nothing to disclose


Prof. Solange Peters, MD, PhD, PD-MER
Professor of Medicine
Department of Oncology
University of Lausanne
Head, Thoracic Clinic
University Hospital
Lausanne, Switzerland
 
Nothing to disclose
 

David Planchard, MD, PhD
Department of Medical Oncology (Thoracic Unit)
Institut-Gustave Roussy
Villejuif, France
 
Consultant: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, GSK, Lilly, MSD, Pfizer, Roche, Sanofi, Pierre Fabre, Merck, and Novartis
 

Naiyer A. Rizvi, MD
Director of Thoracic Oncology
Director of Immunotherapeutics
Division of Hematology and Oncology
Price Chair in Clinical Translational Research
Columbia University Medical Center
New York, New York, USA
 
Consultant: AstraZeneca, Bristol-Myers Squibb, Merck, and Roche.
 

Charles Rudin, MD PhD
Chief, Thoracic Oncology Service
Sylvia Hassenfeld Chair in Lung Cancer Research
Co-Director, Drukenmiller Center for Lung Cancer Research
Professor of Medicine, WCMC
Memorial Sloan Kettering Cancer Center
New York, New York, USA
 
Nothing to disclose
 
 
Julien Sage, PhD
Professor of Pediatrics (Hematology/Oncology) and of Genetics
Stanford University School of Medicine
Stanford, California, USA
 
Nothing to disclose
 
 
Ravi Salgia, MD, PhD
City of Hope Professor and Chair
Department of Medical Oncology and Therapeutics Research
Arthur & Rosalie Kaplan Endowed Chair in Medical Oncology
Associate Director of Clinical Services
City of Hope
Duarte, California, USA
 
Nothing to disclose
 

Professor Rolf Stahel, MD
Professor
Oncology Clinic
University Hospital
Zurich, Switzerland
 
Nothing to disclose
 
 
Dr Daniel SW Tan, MD
Medical Oncology
Senior Consultant
National Cancer Centre Singapore
Clinician-Scientist Fellow, The Genome Institute
Singapore
 
Nothing to disclose
 
 
Yew Oo Tan, MD
Medical Oncologist
Singapore Oncology Consultants (SOC) Group
Singapore
 
Nothing to disclose
 
 
Ming-Sound Tsao, MD
Senior Scientist, Princess Margaret Cancer
Professor of Laboratory Medicine and Pathobiology
M. Qasim Choksi Chair in Lung Cancer Translational Research
University of Toronto
Toronto, Ontario, Canada
 
Nothing to disclose
 
 
Heather Wakelee, MD
Professor of Medicine (Oncology)
Stanford University Medical Center
Stanford, CA
 
Consultant: ACEA, Genentech, Helsinn, Peregrine, and Pfizer
Grants/Research Support: AstraZeneca/MedImmune, Bristol-Myers Squibb, Celgene, Clovis, Exelixis, Gilead Sciences, Lilly, Novartis, Pfizer, Pharmacyclics, Roche/Genentech, and Xcovery

  

Yilong Wu, MD
Vice President
Guangdong General Hospital
Guangdong Academy of Medical Sciences
Director, Guangdong Lung Cancer Institute
Guangzhou, China
 
Nothing to disclose

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Understand the role of NGS-based comprehensive genomic profiling fits into lung cancer management strategies
  • Identify actionable mutational targets and targeted therapies across the spectrum of lung cancer
  • Explain the differences—sensitivity, specificity, and utility—between hot spot panels and hybrid capture NGS comprehensive genomic profiling
  • Detail how evidence-based deployment of genomic profiling can improve clinical outcomes in lung cancer
  • Identify which lung cancer patient populations are appropriate candidates for NGS-based assessments and interpret and act upon results of NGS mutational testing

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Copyright © 2017 by CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

bar

program

slides slides
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © CMEducation Resources, LLC

 
6

 

Key Program Topics Include:

###

###

 

###

###